Tom Quisenaerts

Dr. Tom Quisenaerts


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
LDLoïc Van Dieren
Loïc Van Dieren
TQTom Quisenaerts
Tom Quisenaerts
MLMackenzie Licata
Mackenzie Licata
ABArnaud BEDDOK
Arnaud BEDDOK
ALAlexandre G Lellouch
Alexandre G Lellouch
IGIvana Gorbaslieva
Ivana Gorbaslieva
Introduction: The abscopal effect is a systemic immune response characterized by metastases regression at sites distant from the irradiated lesion. This systematic review aims to explore the immunological mechanisms of action underlying the abscopal effect and to investigate how hyperthermia (HT) can increase the chances of radiotherapy (RT) triggering systemic anti-tumor immune responses. Methods: This review is created in accordance with the PRISMA guidelines. Results and Conclusion: HT and RT have both complementary and synergistic immunological effects. Both methods trigger danger signal release, promoting cytokine and chemokine secretion, which increases T-cell infiltration and facilitates cell death. Both treatments upregulate extracellular tumor HSP70, which could amplify DAMP recognition by macrophages and DCs, leading to stronger tumor antigen presentation and CTL-mediated immune responses. Additionally, the combined increase in cell adhesion molecules (VCAM-1, ICAM-1, E-selectin, L-selectin) could enhance leukocyte adhesion to tumors, improving lymphocyte trafficking and boosting systemic anti-tumor effects. Lastly, HT causes vasodilation and improves blood flow, which might exacerbate those distant effects. We suggest the combination of local radiotherapy with fever-range whole-body hyperthermia to optimally enhance the chances of triggering the abscopal effect mediated by the immune system.

28 November 2025 in Cancers
Verified
Journal Article
Open access
PDF file
IGIvana Gorbaslieva
Ivana Gorbaslieva
TQTom Quisenaerts
Tom Quisenaerts
JBJohannes J. P. M. Bogers
Johannes J. P. M. Bogers
MPMarc Peeters
Marc Peeters
VSVera Saldien
Vera Saldien
DYDirk k Ysebaert
Dirk k Ysebaert
Background/Objectives: Cancer’s complexity can be rationalized through the “hallmarks of cancer,” which define the key biological capabilities driving malignancy. Induced hyperthermia—an adjunctive therapy that elevates body temperature above the normal setpoint for a defined period—has been explored for its modulatory effects on these hallmarks. This systematic review aims to evaluate the effects and mechanisms of induced hyperthermia on tumor cells through the established hallmarks of cancer framework. Methods: A systematic search following the Cochrane guidelines and PRISMA assessment tool was conducted in PubMed and Cochrane Library (2000–2025) to identify reviews on the effects of induced hyperthermia on cancer hallmarks. Studies’ predefined inclusion criteria were independently evaluated by two external teams and graded using PRISMA standards. Results: From the 2015 records screened, 103 studies met the inclusion criteria. Evidence indicates that induced hyperthermia modulates seven of the ten cancer hallmarks. The most well-supported mechanisms of action include (1) the immune system activation (39–41 °C)—enhancing antigen presentation, activating innate/adaptive immune cells, promoting tumor infiltration—and (2) genome instability and mutation (41 °C)—impairing DNA repair pathways and increasing tumor vulnerability. Both hallmarks provide evidence clarifying the mechanistic pathways through which induced hyperthermia exerts its effects. Conclusions: Induced hyperthermia exerts multifaceted, temperature-dependent effects on cancer biology, predominantly through immune activation and genomic destabilization. While it enhances the therapeutic sensitivity of other treatment modalities (e.g., chemotherapy, radiotherapy) and antitumor responses, excessive heating may induce immune suppression and thermotolerance. Optimizing temperature parameters and identifying biomarkers are essential for integrating hyperthermia into targeted and multimodal cancer therapies.

30 November 2023
Verified
Book Chapter
Closed access
PDF file
TQTom Quisenaerts
Tom Quisenaerts
YDYuki Dejonckheere
Yuki Dejonckheere
IDIngri Dahi
Ingri Dahi
FGFrancis Van Glabbeek
Francis Van Glabbeek
PPPascale Pollier
Pascale Pollier
AVAnn Van de Velde
Ann Van de Velde

27 April 2026 in BMC Cancer
Verified
Journal Article
Open access
TQTom Quisenaerts
Tom Quisenaerts
IAIlse Van Der Auwera
Ilse Van Der Auwera
PPPhilip M.P. Poortmans
Philip M.P. Poortmans
DRDries Reynders
Dries Reynders
LDLoïc Van Dieren
Loïc Van Dieren
MMMelanie Machiels
Melanie Machiels
Currently there is a wide practice variation in breast reconstruction surgery after mastectomy for breast cancer patients, especially when radiation therapy (RT) is involved. While it is clear from the scientific literature that immediate implant-based reconstruction has an increased complication rate when postmastectomy Radiation therapy (PMRT) is administered, the jury is out on autologous immediate breast reconstructions (IBR). Nevertheless, some clinicians avoid autologous IBR due to aesthetic outcomes being negatively influenced by PMRT. Others only place tissue expanders, or avoid IBR altogether, when PMRT is indicated. This leads to prolonged periods of time where the patient must live without a new breast, inferior aesthetic outcomes, or an increase in complications. This phase 3 clinical trial, building on the PRADA pilot study, will investigate the efficacy and safety of preoperative RT combined with IBR. In this open-label, multicentre, phase 3, randomised controlled trial, 180 female participants with a new diagnosis of breast cancer will be enrolled. Participants will be randomised into two groups. The first group (control) will receive the standard of care treatment (SoC) consisting of mastectomy followed by PMRT; in this group the breast reconstruction can be either delayed or immediate. The second group (experimental) consists of preoperative RT followed by mastectomy and IBR. After treatment conclusion, follow-up will take place at 3 months, 1, 2, 5, and 10 years after the last study treatment. The primary outcome is the patient reported outcome measure of satisfaction with breasts (BREAST-Q score) at 1 year of follow-up. Secondary outcomes include cosmetic assessment, quality of life, adverse events, treatment duration, and histopathology response rates, tertiary endpoints include oncological survival outcomes according to DATECAN definitions. The trial sponsor is ZAS vzw, and is funded by ‘Kom op tegen kanker’. Preoperative RT has been implemented in multiple other types of cancer and could offer an opportunity to improve aesthetic and quality of life outcomes in breast cancer patients. Based on the PRADA pilot study and similar research, no increase in adverse events or worse oncological outcomes is expected from this change in treatment sequence. ClinicalTrials.gov: NCT06739655; First registration: 17-DEC-2024. Local ZAS Augustinus trial-ID: CTO23023GZA; First registration: 22-APR-2024.